News | Proton Therapy | March 13, 2019

What to Expect from the Proton Therapy Market in 2019-2020

Sales decline continued in 2018, but interest remains high despite financial barriers

What to Expect from the Proton Therapy Market in 2019-2020

March 13, 2019 — The number of new particle therapy rooms ordered worldwide dropped by almost 20 percent in 2018, according to a new report from MEDraysintell, continuing a trend dating back to mid-2016. The report says this trend may change if particle therapy vendors are able to build a strong order book in 2019 and 2020.

Following the large number of new orders for proton therapy equipment reported worldwide during the year 2015, MEDraysintell considered that it was facing a market with strong potential. This positive trend continued until mid-2016, when it began to slow down with a persistent decline in 2017, further confirmed in 2018 as well. Overall, 2018 sales dropped by 62 percent compared to 2015. This decline impacts directly the particle therapy market size (in value by U.S. dollars) evolution, with an anticipated market slowdown of some 25 percent in 2020 compared to 2018. The year 2018 also clearly confirmed the trend in favor of single-room facilities, with 100 percent of the proton therapy orders worldwide oriented towards single-room facilities (compared to less than 40 percent in 2016).

However, a retrospective analysis shows that 2015 was an exceptional year with a record level of orders, and not the new standard expected by the industry, according to the MEDraysintell report. In general, negative publicity, resistance from health authorities and private insurances to reimburse proton therapy, and cost hurdles as a whole have certainly been important factors in the slow adoption of proton therapy facilities in the recent past, the report said. This limited support from investors and healthcare payers remains unchanged and linked to both the higher price of this modality compared to external radiotherapy and the lack of definitive clinical demonstration of superiority (which is under progress).

As of February 2019, there were fewer than 240 particle therapy (mostly proton therapy) treatment rooms available to patients worldwide. This low number represents only 0.3 particle therapy treatment rooms per 10 million people compared to roughly an equivalent 20 radiotherapy systems in the world.

In order to sustain the market growth and to increase the use of proton therapy as an efficient cancer treatment, the PT industry should encourage the research, collection and ongoing publication of clinical evidence, according to MEDraysintell. In addition, stronger marketing is needed in order to grow the referencing of patients toward proton therapy centers. Some mixed signals from the proton therapy area have already been observed — for instance a growing interest of the medical-scientific community stating that at least 10 percent of the population requiring external radiotherapy treatment could benefit from proton therapy. However, this level reached only 0.7 percent in 2018 and almost all operational particle therapy centers are far from saturation levels, with only 17 percent of them able to treat on average over 200 patients per treatment room.

For more information: www.medraysintell.com

Related Proton Therapy Content

VIDEO: Economics of Proton Therapy

VIDEO: The Role of the Physicist in Proton Therapy

360 View of the Gantry Room at the Northwestern Medicine Chicago Proton Center

360 View of the Inclined Beam Room at the Northwestern Medicine Chicago Proton Center

Related Content

Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
Women are more likely to be cured of cancer by radiotherapy but the side effects are worse.

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse. Image by Mark Kostich

News | Radiation Therapy | March 30, 2020
March 30, 2020 — Women undergoing radiotherapy for
A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Prostate Cancer | March 30, 2020
March 30, 2020 — In the wake of the COVID-19 pan
Novel scanners may open door for prognostic assessment in patients receiving cochlear implants

Iva Speck, MD, explains research showing that novel, fully digital, high-resolution positron emission tomography/computed tomography imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment. The research is featured in The Journal of Nuclear Medicine (read more at http://jnm.snmjournals.org/content/current). Video courtesy of Iva Speck, University Hospital Freiburg, Germany.

News | PET-CT | March 26, 2020
March 26, 2020 — Novel, fully digital, high-resolution...
 “Cyclotrons used in Nuclear Medicine Report & Directory, Edition 2020” that describes close to 1,500 medical cyclotrons worldwide
News | Nuclear Imaging | March 10, 2020
March 10, 2020 — MEDraysintell released its new and unique report “...
Accuray Incorporated announced that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife M6 System in Missouri at their state-of-the-art David C. Pratt Cancer Center
News | Stereotactic Body Radiation Therapy (SBRT) | February 27, 2020
February 27, 2020 — Accuray Incorporated announced that Mercy
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Nuclear imaging equipment growth in 2020
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — The nuclear imaging equipment